Research on treating disease with medication. Covers psychedelics, combination cancer therapy, opioid treatment in pregnancy, and personalized guidelines.
Researchers propose regulations around psychedelic medicine use, including risk evaluation and mitigation strategies, practitioner certifications, and decriminalization of psychedelics. They also emphasize the need for funding clinical trials on naturally occurring psychedelics to ensure a pathway for approval.
Researchers at Temple University Health System found that carbonic anhydrase inhibitors reduce inflammation, restore cell function and prevent cognitive impairment in mice with amyloid buildup. CAIs also improved cerebrovascular health and enhanced amyloid-clearing capacity.
Researchers investigated the roles of STAT3α and STAT3β in aggressive breast cancer and found that differential silencing of these isoforms leads to changes in STAT3 activation. This study emphasizes the importance of distinguishing between STAT3 isoforms for accurate cancer diagnosis and therapy.
A study by Michigan Medicine researchers found that nitrous oxide, LSD, and ketamine induce similar changes in brain connectivity, particularly in the cortical 'hot zone' where conscious experience is determined. This common biology may hold the key to using psychedelics as therapeutics.
A majority of people over 50 are open to stopping one or more prescription medicines, but many don't discuss it with their health provider first. The poll shows that comprehensive medication reviews and cost considerations play a crucial role in deprescribing conversations.
Researchers developed a gene signature called CisSig to predict cancer patients' response to cisplatin. The approach aims to overcome the obstacle of interpreting gene signatures in the human body and has been validated in muscle-invasive bladder cancer patients.
Researchers found that bad medical news can make patients more likely to choose brand name drugs over generics, resulting in increased healthcare expenditures. The study suggests that simply reminding patients of the equivalency of generic drugs via text message could improve their decision-making.
The 18th Key Symposium on Healthy Ageing and Longevity takes place in Okinawa, bringing together world experts to discuss the latest research on blue zones. The symposium aims to promote both longevity and healthy ageing to reduce age-related diseases and healthcare burden.
A team of researchers has discovered that a naturally produced chemical in the body helps glioblastoma cells go unrecognized by the immune system. The findings could lead to the development of new and more effective treatments for this aggressive brain cancer.
A new study by Brigham researchers found that 27 high-selling brand-name drugs provided little added clinical benefits despite high costs. The results suggest that Medicare can negotiate prices based on the added benefits of these drugs.
Researchers at UMass Amherst microbiologists have identified an enzyme involved in TB pathogen's survival and growth. The discovery offers a potential target for drug therapies for the deadly disease, which has few effective treatments and caused over 1.6 million deaths worldwide in 2021.
A new target for drug-resistant ovarian cancer has been identified through a preclinical study led by researchers at Penn Medicine. An antibody-drug conjugate targeting B7-H4 showed significant anti-tumor activity and sustained response in treatment-resistant models.
Researchers develop mechanical nanosurgery to destroy tumour cells from within, reducing GBM tumour size universally, including in TMZ-resistant cases. The treatment uses magnetically controlled carbon nanotubes to provide mechanical stimulation, damaging cellular structures and causing tumour cell death.
The new guidelines, developed by 22 experts across three continents, provide a comprehensive approach to diagnosing and treating catatonia. The recommendations include the use of benzodiazepines and electroconvulsive therapy, with attention to special requirements for certain groups.
A study of over 43,000 adults found that parathyroidectomy has no estimated effect on long-term kidney function in older adults. However, early treatment may preserve kidney function in patients younger than 60 years old.
Researchers developed a chelator-free-radiolabeled polymersome capable of long-term multiday PET imaging in vivo. The nanovesicle meets key requirements for targeted cancer therapy, including precision targeting, stable radiotracer binding, and biocompatibility.
A new study reveals that targeting the SWI/SNF protein complex can disrupt PU-1-directed enhancer programs in AML cells, leading to therapeutic responses and rapid tumor regression. The findings also show that these inhibitors have manageable side effects on normal blood cells.
A team of scientists from City University of Hong Kong and HKUST discovered novel, tridimensional compounds with high anticancer activity and low toxicity. These compounds can overcome drug resistance in cancer cells by inducing a different cell death pathway.
Researchers have identified a biomarker signature that can predict which patients with kidney cancer will respond well to immunotherapy. The signature is based on the number of immune cells in and around tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1.
A new imaging technique using a novel nuclear medicine tracer has been developed to improve the treatment of intestinal strictures in Crohn's disease patients. The technique allows for precise differentiation between inflammation and fibrosis, enabling targeted therapy.
Researchers find that patients with destructive nasal lesions may be suffering from cocaine-induced granulomatosis with polyangiitis, a condition often misdiagnosed. Cocaine use can trigger production of antibodies leading to symptoms similar to idiopathic Granulomatosis With Polyangiitis.
A team at UC San Diego developed a biodegradable polymer system to treat rheumatoid arthritis by working with the immune system. The method uses encapsulated all-trans retinoic acid (ATRA) that transforms disease-causing cells into regulatory T cells.
Researchers found that using monoclonal antibodies within two days of a COVID-19 diagnosis reduced the risk of hospitalization or death by 39% compared to those who did not receive treatment. This finding suggests that early treatment with monoclonal antibodies significantly reduced the severity of COVID-19.
Researchers at Rice University have created a new technology called PULSED that can deliver time-released drugs and vaccines for extended periods. The technology uses high-resolution 3D printing and soft lithography to produce microcylinders made of biodegradable polymers, which can be loaded with drugs and release them over time.
Researchers analyzed 2,571 patients treated with monoclonal antibodies and found a 39% reduced risk of hospitalization or death compared to non-treated peers. The study also showed greater benefit in patients with immunocompromising conditions and those treated earlier during the pandemic.
Researchers at Temple University and Johns Hopkins University found that brain-derived neurotrophic factor (BDNF) loss underlies post-myocardial infarction heart failure. BDNF levels can be replenished therapeutically, abolishing damage to heart tissue and enabling recovery.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
Researchers found that dexamethasone prevents cytokine storms in severe COVID-19 patients by inhibiting ion channels and reducing immune cell inflammation. This led to improved lung function and reduced mortality rates. The study's findings provide new insights into the mechanisms of steroid treatment in severe COVID-19.
Researchers found significant decreases in the levels of KRAS, RHOA, RAC1, and CDC42 after PCAI treatment, implicating their role in cancer progression and metastasis. These findings support the potential of PCAIs as potent agents for developing new anticancer therapeutics.
Three pre-clinical studies published in Journal of Pharmaceutical Analysis explore the molecular mechanisms underlying cardiovascular and neurological diseases, providing new avenues for therapeutic strategies.
A study published in Lasers in Surgery and Medicine suggests that light therapy, known as photobiomodulation (PBM), can improve heart function and reduce the thickness of the cardiac wall in middle-aged mice. The research also found improved neuromuscular coordination and a significant survival rate among mice with severe heart disease.
A bacterial molecule, ARBM101, has been found to efficiently lower liver copper levels in a rat model, offering a promising new therapeutic option for Wilson's disease. The treatment approach involves weekly applications followed by month-long breaks, significantly shortening the therapy period.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
Researchers at Texas A&M University have developed the first molecular therapeutic for Angelman syndrome, a devastating neurogenetic disorder. The therapy targets an evolutionarily conserved region in the UBE3A-AS transcript and has shown promising results in clinical trials.
Researchers from Kyushu University found that the single mechanosensitive protein VGLL3 induces fibrosis, thickening and scarring tissue. The study suggests targeting this protein could lead to new treatments against fibrosis.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Three real-world studies published in the Journal of Hepatology and JHEP Reports demonstrate that bulevirtide is well-tolerated and safe for treating chronic hepatitis delta. Long-term suppressive therapy with BLV monotherapy has the potential to reduce viral replication and improve liver function in difficult-to-treat patients.
Researchers studied how tumors adapt to Sotorasib and found that gene amplification and transcriptional programs lead to resistance. This knowledge can help develop targeted treatments for patients with KRAS mutations, potentially increasing survival rates.
A new study published in The Lancet found that an existing drug, sulfadoxine-pyrimethamine, protects pregnant women from sexually transmitted and reproductive tract infections. Researchers tested this drug alongside a promising new treatment, dihydroartemisinin-piperaquine, which showed unique ability to prevent malaria.
A new study describes an optimized method for isolating and identifying nanobodies targeting SARS-CoV-2, which could lead to the development of effective therapies. The approach uses a yeast display method, reducing costs and time required for screening nanobody libraries.
A new study finds that electroconvulsive therapy (ECT), lithium, and clozapine may reduce suicide rates in adolescent men with severe mental illness. The study suggests that early intervention with medico-psychiatric treatment can lower suicide rates among late-teenage boys.
The American College of Chest Physicians released a clinical practice guideline on respiratory management for patients with neuromuscular weakness, providing evidence-based recommendations for mouthpiece ventilation and airway clearance therapies. The guideline aims to improve care for this vulnerable population.
Researchers at Pusan National University have developed a novel FRET-based biosensor to detect double-strand breaks in DNA, providing real-time information on γH2AX. The sensor's sensitivity is higher than conventional immunostaining techniques, making it useful for identifying DNA damage factors and elucidating repair mechanisms.
Glaucoma researchers identify mitochondria as a key source of energy for optic nerve cells, and restoring balance can protect these cells from damage. The study suggests enhancing mitochondrial biogenesis may be a promising treatment strategy.
A phase 2 study found that ANGPTL3 inhibitor therapy reduced triglycerides by up to 70% in patients with severe hypertriglyceridemia who had previously experienced acute pancreatitis. The treatment, evicanumab-dgnb, also showed potential for cardiovascular prevention by reducing apolipoprotein B levels.
A new study by Anglia Ruskin University found that physical activity and pelvic floor exercises can effectively increase latency time in men with premature ejaculation. The research suggests exercise as a promising non-pharmacological treatment option, potentially reducing the reliance on drugs with side effects.
A new drug called CADD522 blocks a gene associated with driving bone cancer's spread, increasing survival rates by 50% in mice implanted with human bone cancer. The breakthrough treatment shows promise in all main bone cancer subtypes and has the potential to save lives and reduce disability.
A new cutaquig study found that increasing infusion volume per site resulted in a reduction of injection sites, while increasing infusion rates decreased infusion duration. The research also showed that dosing every other week demonstrated equivalency to trough levels with weekly dosing.
A new study shows that transcatheter mitral valve repair significantly reduces hospitalizations by almost 50 percent and death by nearly 30 percent in heart failure patients with severe mitral regurgitation. The procedure, using Abbott's MitraClip system, improves symptoms, reduces hospitalizations, and leads to longer survival.
Researchers developed synthetic peptide nanonets that selectively entrap bacteria, rendering them vulnerable to antimicrobial components. The nanonets displayed both trapping and killing functionalities, demonstrating potential as an anti-infective strategy.
A study published in NEJM Evidence found that seizures can be predicted at least 35 minutes before onset in patients with temporal lobe epilepsy. This breakthrough discovery has significant implications for developing more effective therapies for this common seizure disorder, which affects over 50 million people globally.
A phase 2 clinical trial shows that treating resectable stage 3 and 4 melanoma patients with pembrolizumab both before and after surgery greatly improves outcomes compared to pembrolizumab given only after surgery. This approach resulted in significantly longer event-free survival rates.
Researchers at VCU Massey Cancer Center found that simultaneous activation of Prdm16 and Smad4 proteins slows down pancreatic cancer progression. The study suggests a novel therapeutic approach to tackle this deadly disease.
Researchers have designed a compound that targets and breaks down phosphorylated p38, a posttranslationally modified protein closely associated with Alzheimer's disease. This breakthrough could provide a novel treatment for the disease and open up opportunities for future treatments of other 'undruggable' diseases.
A new review paper from Mayo Clinic outlines how obesity impacts common tests used to diagnose heart disease, such as ECG, CT scan, MRI, and echocardiogram. The study highlights the need for alternative approaches to prevent weight gain in patients with heart disease.
William L. Lombardi, MD, receives the TCT Geoffrey O. Hartzler Master Operator Award for his technical excellence and leadership in complex coronary disease therapies. He is recognized for developing novel CTO techniques and technologies to improve patient outcomes.
Scientists at Aarhus University and Berkeley Laboratory developed a method called RNA origami to design artificial RNA nanostructures. The technique allowed for the discovery of rules and mechanisms for RNA folding that will make it possible to build more ideal RNA particles for use in RNA-based medicine.
A study found that over 80% of American adults with type 2 diabetes meet the criteria to use GLP-1 RAs or SGLT2is, but only a small percentage are using them. The medications have a substantially higher cost than current first-line treatments, making it difficult for patients to access them.
A smartphone app-based cognitive behavioral therapy program lowered blood sugar levels and improved health behaviors in patients with diabetes. The study found a clear 'dose effect,' where participants completing more lessons saw greater benefits.
The ESMO Targeted Anticancer Therapies Congress 2023 features presentations on drug discovery and development for various targets, precision medicine, and early clinical trial methodology. Keynote lectures highlight novel insights in mutational signatures and epigenetic therapies.